- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Cipla's Q3FY26 performance saw flat revenue at INR 7,074 Cr, but profit (PAT) dipped 57% YoY to INR 676 Cr, with EBITDA also down significantly to INR 1,255 Cr.
India business was a bright spot, growing strong double-digits, fueled by respiratory outperformance and strategic moves. Cipla inked a deal to exclusively market Pfizer's key brands in India and acquired Inzpera Healthsciences for its paediatric portfolio, boosting market presence.
In North America, Albuterol maintains its #1 spot with a 22% market share. However, Lanreotide supply faces temporary interruption, expected to resume H1 FY27. Upcoming pipeline launches, including 4 respiratory (like gAdvair) and 4 peptide products by FY27, are key growth drivers. The company also launched India’s first Lung Diagnostics & Wellness Center in Delhi.
Financially, despite the profit dip, Cipla maintains a robust balance sheet with Net Cash of INR 10,229 Cr. Management's outlook highlights continued focus on India market expansion, consumer wellness growth, and a strong product pipeline to drive future performance.